急性心肌梗死后口服华法林的疗效及安全性

Efficacy and safety of warfarin treatment on the patients with acute myocardial infarction

目的 :研究急性心肌梗死后患者口服华法林的疗效及安全性。方法 :10 0例急性心肌梗死住院患者 ,随机分成 2组。华法林组服用华法林 3mg/d开始 ,根据国际标准化比值 (INR)调整华法林剂量 ,维持INR2 .0～ 3.0 ;阿司匹林组口服肠溶阿司匹林 10 0mg/d。 2组均随访 1a。结果 :华法林组新发心肌梗死发生率、不稳定性心绞痛发生率 ,心血管病因再住院率、心血管病因死亡率均低于肠溶阿司匹林组 (P <0 .0 5 ) ;华法林组总出血率高于肠溶阿司匹林组 (P <0 .0 5 ) ,但大多为能够耐受的小出血 ,不影响治疗。结论

Aim: To observe the efficacy and safety of warfarin treatment on the patients with acute myocardial infarcton. Methods: A total of 100 hospitalized patients with acute myocadial infarction from 2000 to 2002, were randomely divided into two group. Group I used warfarin with the dose of 3 mg/d at start, according to international normalized ratio(INR) to stantard therapy.Another group were administrated with 100 mg/d of Asparin.Both of the two group were following-up for 1 year.Results: The rates of new myocardial infarction, unstable angina,cardiovascular death, and cardiovascular rehospitalisation were lower in Group I than those in the asparin group(P<0.05).There was a significant changes of minor bleeds in the warfarin group ( P<0.05).Conclusion: Treatment with warfarin in patients of acute myocardial infarction is effective and safety.